Cargando…
Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262697/ https://www.ncbi.nlm.nih.gov/pubmed/29877291 http://dx.doi.org/10.2169/internalmedicine.9884-17 |
_version_ | 1783375162009190400 |
---|---|
author | Nakahara, Yoshiro Fukui, Tomoya Shirasawa, Masayuki Harada, Shinya Kusuhara, Seiichiro Takakura, Akira Yokoba, Masanori Mitsufuji, Hisashi Kubota, Masaru Katagiri, Masato Sasaki, Jiichiro Masuda, Noriyuki Inukai, Madoka Sekiguchi, Tomoko Naoki, Katsuhiko |
author_facet | Nakahara, Yoshiro Fukui, Tomoya Shirasawa, Masayuki Harada, Shinya Kusuhara, Seiichiro Takakura, Akira Yokoba, Masanori Mitsufuji, Hisashi Kubota, Masaru Katagiri, Masato Sasaki, Jiichiro Masuda, Noriyuki Inukai, Madoka Sekiguchi, Tomoko Naoki, Katsuhiko |
author_sort | Nakahara, Yoshiro |
collection | PubMed |
description | We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab as a third-line chemotherapy. After four cycles of nivolumab treatment, a partial response was observed in the brain and at the primary tumor site. Nivolumab treatment has been continued for 11 months without progression. Immunohistochemistry revealed that the programmed death-ligand 1 (PD-L1) expression was 0% (according to the tumor proportion score). Our case indicates that the efficacy of programmed cell death 1 inhibitors is not solely predicted by the PD-L1 status, and that immune checkpoint inhibitors might be effective for the treatment of central nervous system metastasis. |
format | Online Article Text |
id | pubmed-6262697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-62626972018-11-30 Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma Nakahara, Yoshiro Fukui, Tomoya Shirasawa, Masayuki Harada, Shinya Kusuhara, Seiichiro Takakura, Akira Yokoba, Masanori Mitsufuji, Hisashi Kubota, Masaru Katagiri, Masato Sasaki, Jiichiro Masuda, Noriyuki Inukai, Madoka Sekiguchi, Tomoko Naoki, Katsuhiko Intern Med Case Report We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) /anaplastic lymphoma kinase (ALK) rearrangement. He was treated with nivolumab as a third-line chemotherapy. After four cycles of nivolumab treatment, a partial response was observed in the brain and at the primary tumor site. Nivolumab treatment has been continued for 11 months without progression. Immunohistochemistry revealed that the programmed death-ligand 1 (PD-L1) expression was 0% (according to the tumor proportion score). Our case indicates that the efficacy of programmed cell death 1 inhibitors is not solely predicted by the PD-L1 status, and that immune checkpoint inhibitors might be effective for the treatment of central nervous system metastasis. The Japanese Society of Internal Medicine 2018-06-06 2018-11-01 /pmc/articles/PMC6262697/ /pubmed/29877291 http://dx.doi.org/10.2169/internalmedicine.9884-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Nakahara, Yoshiro Fukui, Tomoya Shirasawa, Masayuki Harada, Shinya Kusuhara, Seiichiro Takakura, Akira Yokoba, Masanori Mitsufuji, Hisashi Kubota, Masaru Katagiri, Masato Sasaki, Jiichiro Masuda, Noriyuki Inukai, Madoka Sekiguchi, Tomoko Naoki, Katsuhiko Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma |
title | Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma |
title_full | Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma |
title_fullStr | Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma |
title_full_unstemmed | Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma |
title_short | Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma |
title_sort | intracranial response to nivolumab in a patient with pd-l1-negative lung adenocarcinoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262697/ https://www.ncbi.nlm.nih.gov/pubmed/29877291 http://dx.doi.org/10.2169/internalmedicine.9884-17 |
work_keys_str_mv | AT nakaharayoshiro intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT fukuitomoya intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT shirasawamasayuki intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT haradashinya intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT kusuharaseiichiro intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT takakuraakira intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT yokobamasanori intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT mitsufujihisashi intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT kubotamasaru intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT katagirimasato intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT sasakijiichiro intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT masudanoriyuki intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT inukaimadoka intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT sekiguchitomoko intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma AT naokikatsuhiko intracranialresponsetonivolumabinapatientwithpdl1negativelungadenocarcinoma |